Glucagon Like Peptide Agonists as Therapy for Treatment of Cardiometabolic Diseases

$50.00$75.00

Authors: R B Singh, Mahmood Moshiri, Osama Elmarghi, Galal elkilany, Jan Fedacko, and Gushchina Yulia
Page Range: 145-156
Published in: World Heart Journal, 14#2 (2022)
ISSN: 1556-4002

ISBN: N/A Category:

Table of Contents

ABSTRACT

The glucagon-like peptide-1 (GLP-1) has a broad pharmacological potential. After modification bio-chemically for enhanced potency and sustained action, GLP-1 receptor agonists are successfully used for the treatment of type-2 diabetes (T2DM) and cardiovascular diseases (CVDs). The beneficial effects of GLP-1 render it for the development of pharmacotherapies by developing long-acting analogues. At present, GLP-1 receptor agonists are injected twice daily (exenatide b.i.d.), once daily (lixisenatide and liraglutide), or once weekly (exenatide once weekly, dulaglutide, albiglutide, and semaglutide). A daily semaglutide oral tablet has been found to be as effective as once-weekly subcutaneous preparation. All GLP-1 receptor agonists have common mechanisms of action. There is an augmentation of hyperglycemia-induced insulin secretion, suppression of glucagon secretion, deceleration of gastric emptying, and a decline in calorie intake and body weight. Exenatide b.i.d, and lixisenatide are short-acting with reduced effectiveness, whereas liraglutide, once-weekly, exenatide, dulaglutide, albiglutide, and semaglutide have more profound effects on overnight and fasting plasma glucose and HbA1c. GLP-1 receptor agonists are recommended as the first injectable glucose-lowering therapy for T2DM, even before insulin treatment, although they can be combined with (basal) insulins. More recently, semaglutide has been found to possess greater efficacy with respect to lowering plasma glucose as well as body weight. Since 2016, GLP-1 receptor agonists have been found to prevent CVDs, hence guidelines recommend treatment with these agents in patients with pre-existing atherosclerotic CVDs. Since sodium/glucose cotransporter-2 (SGLT-2) inhibitor therapy also reduces CVDs, in particular heart failure, the individual risk of ischemic or complications of heart failure should guide the choice of treatment. GLP-1 receptor agonists may also help prevent renal complications of T2DM. Novel indications for GLP-1 receptor agonists, such as T1DM, neurodegenerative diseases, and psoriasis, indicate that these agents have the potential for further development.

Keywords: Glucagon, GLP-1, insulin, diabetes, obesity; incretin, hormone

REFERENCES

[1] Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism 2019; 30: 72-130. https://doi.org/10.1016/j.molmet.2019.09.010.
[2] Morrow NM, Hanson AA, Mulvihill EE. Distinct identity of GLP-1R, GLP-2R, and GIPR expressing cells and signaling circuits within the gastrointestinal tract. Front. Cell Dev Biol 2021. https://doi.org/10.3389/fcell.2021.703966.
[3] Grunddal KV, Jensen EP, Ørskov C, Andersen DB, Windeløv JA, Poulsen SS, Rosenkilde MM, Knudsen LB, Pyke C, Holst JJ. Expression profile of the GLP-1 receptor in the gastrointestinal tract and pancreas in adult female mice. Endocrinology 2022; 163 (1): bqab216. https://doi.org/ 10.1210/ endocr/bqab216.
[4] Patzelt C, Tager HS, Carroll RJ, Steiner DF. Identification and processing of proglucagon in pancreatic islets. Nature 1979; 282: 260-266.
[5] Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochemical J 1982; 207: 381-388.
[6] Thim L, Moody AJ. The amino acid sequence of porcine glicentin. Peptides 1981; 2 (Suppl. 2): 37-39.
[7] Holst JJ. Evidence that glicentin contains the entire sequence of glucagon. Biochem J 1980; 187: 337-343.
[8] Moody AJ, Holst JJ, Thim L, Jensen SL. Relationship of glicentin to proglucagon and glucagon in the porcine pancreas. Nature 1981; 289: 514-516.
[9] Bataille D, Tatemoto K, Gespach C, Jornvall H, Rosselin G, Mutt V. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Letters 1982; 146: 79-86.
[10] Thim L, Moody AJ. Purification and chemical characterization of a glicentin-related pancreatic peptide (proglucagon fragment) from porcine pancreas. Biochim Biophys Acta 1982; 703: 134-141.
[11] Kang YM, Jung CH. Cardiovascular effects of glucagon-like peptide-1 receptor agonists. Endocrinol Metab 2016; 31 (2). doi:10.3803/ EnM. 2016.31.2.258
[12] Dietle AL, Campanale MC, Ostroff JL. GLP-1 receptor agonists: an alternative for rapid-acting insulin? US Pharm 2016; 41 (10) (Diabetes suppl): 3-6.
[13] Nauck MA, Quast DR. Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes mellitus. Findings from SUSTAIN 6 and PIONEER 6. Front Endocrinol 2021; 12: 645566. doi: 10.3389/fendo.2021.645566.
[14] Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381: 841-851.
[15] Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32 (5): 762-768. doi:10.2337/dc08-1797.
[16] Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art. Mol Metab 2021; 46: 101102. doi: 10.1016/j.molmet. 2020. 101102.
[17] Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, Wilhelm K, Trautmann M, Shen LZ, Porter LE; DURATION-1 Study Group. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010; 33 (6): 1255-1261. doi:10.2337/dc09-1914.
[18] Davies M, Heller S, Sreenan S, Sapin H, Adetunji O, Tahbaz A, Vora J. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care 2013; 36 (5): 1368-1376. doi: 10.2337/dc12-1333.
[19] Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322.
[20] Tamborelane WV, Perez MB, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T; Ellipse Trial Investigators. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med 2019; 381: 637-646.
[21] Woodward HN, Anderson SL. Once-weekly albiglutide in the management of type 2 diabetes: patient considerations. Patient Prefer Adherence 2014; 8: 789-803. doi:10.2147/PPA.S53075
[22] Ahren B, Johnson S, Stewart M, Cirkel DT, Yang F, Perry C, Feinglos MN; HARMONY 3 Study Group. HARMONY 3: 104‐week randomized, double‐blind, placebo‐ and active‐controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 2014; 37: 2141‐2148. doi: 10.2337/dc14‐0024.
[23] Weissman P, Carr M, Ye J, Cirkel DT, Stewart M, Perry C, Pratley R. HARMONY 4: randomised clinical trial comparing once‐weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled on metformin with or without sulfonylurea. Diabetologia 2014; 57 (12): 2475-2484. doi: 10.1007/s00125‐014‐3360‐3.
[24] Prately R, Nauck M, Barnett A, Feinglos MN, Ovalle F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, Rosenstock J; HARMONY 7 study group. Once‐weekly albiglutide versus once‐daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open‐label, multicentre, non‐inferiority phase 3 study. Lancet Diabetes Endocrinol 2014; 2: 289‐297. doi: 10.1016/s2213‐8587(13)70214‐6.
[25] Leiter L, Carr M, Stewart M, Jones-Leone A, Scott R, Yang F, Handelsman Y. Efficacy and safety of the once‐weekly GLP‐1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care 2014; 37: 2723‐2730. doi: 10.2337/dc13‐2855.
[26] Fala L. Trulicity (Dulaglutide): a new GLP-1 receptor agonist once-weekly subcutaneous injection approved for the treatment of patients with type 2 diabetes. Am Health Drug Benefits 2015; 8 (Spec Feature): 131-134.
[27] Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, Malik R, Bethel MA, Cox DA. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care 2021; 44 (3): 765-773. doi: 10.2337/dc20-1473.
[28] Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014; 37: 2168–2176.
[29] Dagenais GR, Rydén L, Leiter LA, Lakshmanan M, Dyal L, Probstfield JL, Atisso CM, Shaw JE, Conget I, Cushman WC, Lopez-Jaramillo P, Lanas F, Munoz EGC, Pirags V, Pogosova N, Basile J, Sheu WHH, Temelkova-Kurktschiev T, Raubenheimer PJ, Keltai M, Hall S, Pais P, Colhoun HM, Riddle MC, Gerstein HC Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovasc Diabetol 2020; 19 (1): 199. doi: 10.1186/s12933-020-01179-1.
[30] Fellner C. Novel treatments target type-2 diabetes. P T 2016; 41 (10): 650-653.
[31] Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247-2257.
[32] Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375 (19): 1834-1844.
[33] Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, Serusclat P, Violante R, Watada H, Davies M; PIONEER 3 Investigators. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA 2019; 321 (15): 1466-1480.
[34] Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, Lingvay I, Søndergaard AL, Treppendahl MB, Montanya E; PIONEER 2 Investigators. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 Trial. Diabetes Care 2019; 42 (12): 2272-2281.
[35] Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ; PIONEER 4 investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019; 394 (10192): 39-50.
[36] Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diab Endocrinol 2019; 7 (10): 776–785.
[37] Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, Hansen G, Grove KL, Pyke C, Raun K, Schäffer L, Tang-Christensen M, Verma S, Witgen BM, Vrang N, Bjerre Knudsen L The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014; 124: 4473–4488.
[38] Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, Buckley ST, Farkas E, Fekete C, Frederiksen KS, Helms HCC, Jeppesen JF, John LM, Pyke C, Nøhr J, Lu TT, Polex-Wolf J, Prevot V, Raun K, Simonsen L, Sun G, Szilvásy-Szabó A, Willenbrock H, Secher A, Knudsen LB, Hogendorf WFJ. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 2020; 5 (6): e133429. epub Mar 26, 2020.
[39] Nishizawa M, Nakabayashi H, Uehara K, Nakagawa A, Uchida K, Koya D. Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways. Am J Physiol 2013; 305: E376–E387.
[40] Hansen L, Deacon CF, Ørskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140: 5356–5363.
[41] Cornelissen G, Halberg F. Time restricted feeding: meal time matters. Int J Clin Nutr 2012; 12 (1): 1-10.